# Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19

> **NCT05679479** · PHASE3 · COMPLETED · sponsor: **Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd** · enrollment: 108 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Meplazumab for injection
- **OTHER:** Normal saline

## Key facts

- **NCT ID:** NCT05679479
- **Lead sponsor:** Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-19
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-04-18
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05679479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05679479, "Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05679479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*